Relieves heartburn. ANDA 219115, held by Alembic. Dexlansoprazole.
As of Nov 21, 2026, ANDA 219115 (Dexlansoprazole), held by Alembic, was first approved by FDA on Nov 12, 2025, with 0 approved supplements and 0 published complete response letters.
Dexlansoprazole delayed-release capsules are a proton pump inhibitor (PPI) indicated in patients 12 years of age and older for:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 12, 2025 | Original application | Approved | None posted |
| Dexlansoprazole30MG · capsule, delayed release;oral | Dexlansoprazole | Rx |
| Dexlansoprazole60MG · capsule, delayed release;oral | Dexlansoprazole | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters